Depo-Provera Settlement Amounts: What Similar Cases Have Settled For

Published: March 20, 2026 10 min read

One of the first questions women ask is: how much could I actually receive? That's a fair question. The honest answer in April 2026 is that no Depo-Provera settlements have been announced. The litigation is still in its early phases. What we can do is look at comparable pharmaceutical MDLs to understand realistic benchmarks — and explain what factors will determine individual Depo-Provera settlement amounts when that time comes.

No Settlement Announced Yet — And That's Normal

Pharmaceutical MDL cases almost never settle in the first two to three years. The process requires both sides to understand the full strength of the evidence before a defendant like Pfizer/Pharmacia will agree to a global number. That understanding develops through:

• Expert discovery: Both sides commission scientific experts. Plaintiff experts establish causation; defense experts challenge it. The court rules on what expert testimony is admissible (Daubert process).
• Internal document review: Plaintiffs' attorneys are demanding Pfizer's internal communications about what the company knew about meningioma risk and when. These documents can be highly damaging — and their contents shape settlement leverage.
• Bellwether verdicts: One or two jury verdicts tell both sides how juries actually react to the evidence. A $15 million plaintiff verdict is a very different settlement signal than a $2 million defense win.

The absence of a settlement in 2026 is not a sign of a weak case. It's the normal pre-settlement phase of large pharmaceutical litigation.

What Comparable Pharmaceutical MDLs Tell Us

While no Depo-Provera-specific numbers exist yet, we can look at settlements in similar cases where a pharmaceutical manufacturer was accused of failing to warn about a serious injury risk.

Essure (Bayer) — Pelvic Device Injuries

Bayer's Essure intrauterine device litigation (MDL 2705) involved thousands of women who claimed the device caused chronic pain, organ perforation, and autoimmune symptoms. Bayer agreed to pay $1.6 billion in 2020 to settle approximately 39,000 claims — an average of roughly $41,000 per claim, though individual amounts varied widely based on injury severity. The most serious cases settled for several hundred thousand dollars.

Risperdal (Johnson & Johnson) — Gynecomastia

J&J paid over $2.2 billion in 2013 to resolve claims related to Risperdal, an antipsychotic linked to abnormal breast development in male patients. Individual verdicts in Risperdal cases reached into the tens of millions — though the average settlement per claim was significantly lower after a mass resolution framework was negotiated.

Xarelto (Bayer/J&J) — Bleeding Events

The Xarelto MDL (MDL 2592) involved over 25,000 plaintiffs who claimed the blood thinner caused uncontrollable bleeding events. The global settlement was $775 million for approximately 25,000 claimants — an average of roughly $31,000 per case, with serious injury cases receiving significantly more.

NuvaRing (Merck) — Blood Clots

Merck settled approximately 3,800 NuvaRing cases for $100 million in 2014. Average per-case values were modest (around $26,000), but NuvaRing cases had a different injury profile — primarily blood clot complications — and litigation strength compared to what experts believe exists in Depo-Provera cases.

The Depo-Provera Comparison

Depo-Provera cases involve brain tumors — some requiring surgery, radiation, and ongoing monitoring; some causing permanent neurological deficits; some resulting in death. The injury severity in Depo-Provera cases is generally more serious than in many comparable pharmaceutical MDLs. That, combined with the FDA's black box warning providing clear evidence of company knowledge failure, suggests the settlement value range for serious cases could be higher than the MDL averages cited above.

Mass tort litigation analysts following MDL 3140 informally suggest serious cases (surgery required, significant neurological impact) could settle in the range of $150,000 to $600,000 or more. Moderate cases (diagnosed but no surgery yet, active monitoring) may settle for less. These are not guarantees — they are informed projections based on comparable litigation and should be understood as speculative until actual bellwether verdicts provide real data.

What Affects Your Individual Depo-Provera Settlement Amount

Within any global settlement framework, individual case values are driven by factors specific to you:

Duration and Dose of Depo-Provera Use

The longer you used Depo-Provera, the stronger the causation argument. Women with 10+ years of use have a more compelling exposure narrative than those with 2–3 years. That said, the cutoff for eligibility has generally been set at 2+ years — cases above that threshold are evaluated on a spectrum.

Meningioma Severity and Grade

Grade I meningiomas (benign, slow-growing) that are being monitored without treatment represent real harm but lower immediate damages than Grade II (atypical) or Grade III (malignant) tumors. Tumor location also matters — skull base meningiomas near critical structures cause more neurological disruption than small convexity tumors.

Treatment Required

Cases involving craniotomy (brain surgery), gamma knife radiosurgery, radiation therapy, or post-surgical neurological complications are more valuable than "watch and wait" cases. Medical bills from surgery and recovery can easily reach $150,000 to $400,000.

Documented Neurological Impact

Vision loss, hearing loss, cognitive changes, speech difficulties, balance problems, seizures — any documented neurological deficit resulting from the tumor or its treatment increases the damages available to claim.

Lost Income and Career Impact

Women who were unable to work during treatment and recovery — or who have permanent disability affecting their earning capacity — can claim lost wages. The economic component of damages can be substantial for working-age plaintiffs.

Quality of Life and Pain and Suffering

Non-economic damages compensate for the pain, fear, and reduced quality of life caused by a brain tumor diagnosis. These vary by state law and jury norms, but they are often the largest component of damages in serious personal injury cases.

Documentation Quality

Claims with complete, organized medical records supporting both Depo-Provera use and meningioma treatment are worth more in settlement than cases with documentation gaps. Start gathering records now — don't wait.

Types of Damages You Can Claim

In a Depo-Provera meningioma claim, you may be able to recover:

• Medical expenses: All past and future costs of diagnosis, surgery, radiation, monitoring, medications, and rehabilitation
• Lost wages: Income lost during treatment and recovery
• Loss of earning capacity: If the injury permanently limits your ability to work
• Pain and suffering: Compensation for physical pain and emotional distress
• Loss of consortium: Compensation for damage to your relationship with a spouse or partner (in some states)
• Punitive damages: In some cases, if a defendant's conduct was particularly egregious, courts may award additional punitive damages. These are less common in settlement frameworks but possible in individual trial verdicts.

How MDL Settlement Tiers Work

When a global settlement is eventually negotiated in MDL 3140, it will likely use a tiered system to distribute the total settlement fund among plaintiffs. Here's how tiers typically work in pharmaceutical MDLs:

Tier 1 (Highest value): Most serious cases — surgery performed, significant neurological deficits, long use duration (e.g., 10+ years), Grade II-III tumors

Tier 2 (Mid-range): Moderate cases — diagnosed with meningioma requiring treatment, meaningful use duration (5–10 years), clear impact on daily life

Tier 3 (Lower value): Less severe cases — small tumor under monitoring, shorter use duration, limited documented impact

Where your case falls in this tier structure will depend on your specific medical records, treatment history, and documented damages. Your attorney's job is to present your case in the most compelling light within the framework the settlement establishes.

When to Expect Settlement Talks

Realistic timeline for settlement discussions in MDL 3140:

• 2026: No global settlement. Focus on bellwether preparation.
• Late 2026 – Early 2027: First bellwether trials. Results begin to define settlement value range.
• 2027: If verdicts favor plaintiffs, settlement talks may begin in earnest.
• 2027–2028: Possible announcement of a global settlement framework.
• 2028–2029: Individual claim administration. Payments distributed.

Filing early matters because: (1) you preserve your right to participate before the statute of limitations runs, and (2) early filers have more complete documentation reviewed and may be better positioned in the bellwether process.

Realistic Expectations

Here's what to keep in mind as you research Depo-Provera settlement amounts:

• No one can promise you a specific number. Anyone who does is misleading you.
• Settlement values span a very wide range — from tens of thousands to potentially hundreds of thousands for the most serious cases.
• Your individual recovery depends on your specific facts, not an average.
• Attorney fees (typically 33–40%) come out of your settlement. Factor this into your expectations.
• The litigation will take years. Plan accordingly.
• Filing sooner rather than later protects your rights without committing you to any specific outcome.

For more on the litigation process, see: Depo-Provera MDL 3140 Explained and Depo-Provera Lawsuit 2026 Update.